Pediatric Study Planning Should Occur Early In Drug Development, FDA Says
Executive Summary
Sponsors of drugs for serious or life-threatening diseases should discuss pediatric study plans with FDA at pre-IND and end-of-Phase I meetings, the agency recommends in a draft guidance
You may also be interested in...
FDA Pediatric Study Bill Clears Senate, Will Sunset With Exclusivity Grants
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials